36 completed, 5 recruiting, 3 active not recruiting, 3 unknown. 15 Phase 3, 14 Phase 4, 12 Phase 2, 9 Phase 1, 2 Not applicable.
Follow Testosterone Propionate: new trials by email Literature Review of Testosterone Propionate trials Research Report on Testosterone Propionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Testosterone enanthate - Hypogonadism, Male | Phase 3 | Recruiting | Halozyme Therapeutics | 100 | 2025-03-07 | 2026-11-06 |
| Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging - Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8 | Phase 4 | Recruiting | Roswell Park Cancer Institute | 600 | 2025-01-15 | 2026-05-14 |
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 3 | 2024-12-19 | 2026-08-07 |
| Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration Testosterone injection, Testosterone gel, Testosterone Oral - Healthy | Early Phase 1 | Completed | Sports Medicine Research and Testing Laboratory | 14 | 2024-11-27 | 2024-12-03 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| Testosterone Treatment in Men With Chronic Kidney Disease Jatenzo Pill - Hypogonadism, Male, Kidney Disease, Chronic | Phase 2 | Recruiting | St. Louis University | 20 | 2022-03-15 | 2026-04-30 |
| Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Testosterone Undecanoate, Enzalutamide - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2022-03-07 | 2026-09-29 |
| Patient Satisfaction After Switching to Oral Testosterone Undecanoate Jatenzo - Testosterone Deficiency | Phase 4 | Completed | University of Miami | 41 | 2021-06-18 | 2023-12-14 |
| The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population Fortesta, Estradiol - Hypogonadism, Gender Identity Dysphoria | Recruiting | Walter Reed National Military Medical Center | 75 | 2021-03-09 | 2025-07-29 | |
| Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone Best Practice, Quality-of-Life Assessment, Questionnaire Administration - Hypogonadism, Malignant Urinary System Neoplasm | Phase 1 | Active not recruiting | Emory University | 56 | 2021-01-25 | 2026-05-26 |
| Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers. Bupropion, Anastrozole, Testosterone cyclopentylpropionate - Healthy Volunteers | Phase 1 | Completed | Parc de Salut Mar | 9 | 2020-12-03 | 2021-04-26 |
| Vogelxo(R) ABPM Study in Hypogandal Men Vogelxo - Hypogonadism, Male | Phase 4 | Completed | Upsher-Smith Laboratories | 122 | 2020-08-28 | 2024-10-18 |
| A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Aveed Injectable Product, Fortesta, Testim - Hypogonadism, Hypogonadism, Male | Phase 4 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 673 | 2020-06-30 | 2025-03-14 |
| Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection - Muscle Atrophy, Surgery | Phase 2 / Phase 3 | Unknown | The Stone Research Foundation for Sports Medicine and Arthritis | 15 | 2020-05-08 | 2021-08-31 |
| Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations Testosterone Undecanoate, Sesame Oil - Caloric Restriction, Exercise | Phase 4 | Completed | Pennington Biomedical Research Center | 34 | 2019-09-23 | 2022-10-07 |
| Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Xiaflex®, Aveed - Peyronie's Disease (PD) | Phase 4 | Completed | Men's Health Boston | 20 | 2019-01-14 | 2020-12-31 |
| COMbination of Bipolar Androgen Therapy and Nivolumab Testosterone cypionate, Nivolumab - Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 45 | 2018-09-05 | 2024-02-20 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | University of Washington | 36 | 2018-08-29 | 2025-09-29 |
Showing 20 of 52. Sign in to see all of them.
Hypogonadism (22) · Eunuchism (8) · Prostatic Neoplasms (7) · Sexual Dysfunctions, Psychological (4) · Breast Neoplasms (3) · Motor Activity (3) · Metabolic Syndrome (2) · Sexual Dysfunction, Physiological (2) · Antisocial Personality Disorder (1) · Anxiety Disorders (1) · Disease (1) · Dyspareunia (1) · Ejaculatory Dysfunction (1) · Endocrine System Diseases (1) · Erectile Dysfunction (1)
Eli Lilly and Company (8) · Lipocine Inc. (4) · Bayer (3) · BioSante Pharmaceuticals (3) · Gulhane School of Medicine (3) · Roswell Park Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Texas at Austin (2) · University of Washington (2) · VA Office of Research and Development (2) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Endo USA Inc., a Keenova Therapeutics Company (1)
United States (39) · Canada (5) · Germany (5) · Turkey (Türkiye) (3) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Denmark (1) · France (1) · Italy (1) · Puerto Rico (1) · South Korea (1) · Sweden (1) · United Arab Emirates (1)
Anthony DelConte, MD (3) · Michael C Snabes, MD, PhD (3) · Michael Schweizer (2) · Abraham Morgentaler, MD (1) · Ahmed Aly (1) · Ana M Aldea Perona, MD PhD (1) · Anthony Delconte, MD (1) · Chad R Heatwole, MD, MS-CI (1) · Charles L. Loprinzi, MD (1) · David Hernandez (1) · Geoff Miller, PhD (1)
PMID 38224135, PMID 17470735, PMID 17983892, PMID 19375217, PMID 21252493, PMID 21689131, PMID 21717386, PMID 22172433, PMID 23343764, PMID 23730808, PMID 24089589, PMID 24968251, PMID 25123988, PMID 26158605, PMID 26498057, PMID 26549704, PMID 29656500, PMID 32853647, PMID 33735389, PMID 34191621, PMID 34278044, PMID 34994093, PMID 35027909, PMID 36796647, PMID 36949577, PMID 38167882, PMID 39252657, PMID 40279652, PMID 40900971
2009 (1), P01CA005826 (1), P30CA008748 (1), P30CA015704 (1), P30CA033572 (1), P30CA138292 (1), P50CA097186 (1), U10CA180820 (1)